To compare the efficacy and safety of first-line treatments for patients with advanced hepatocellular carcinoma (HCC) using a Bayesian network meta-analysis.
Key Findings:
HAIC-based regimens, particularly sorafenib plus HAIC and HAIC_FO, ranked highest for both PFS and OS.
Several immunotherapy-based combinations showed significant survival benefits without increasing severe adverse events.
Subgroup analyses indicated consistent benefits across various clinical subgroups.
Interpretation:
HAIC-based strategies and selected immunotherapy combinations appear to provide superior survival outcomes as first-line treatment for advanced HCC.
